Akero to be acquired by Novo Nordisk for up to $5.2B; $54/share cash + $6 CVR

Akero Therapeutics, Inc.

Shareholders get $54.00 cash per share at closing (equity value ~$4.7B) plus a CVR worth up to $6.00 per share if FDA approves efruxifermin for MASH-cirrhosis by June 30, 2031.
Total potential equity value ~$5.2B; upfront cash represents a 19% premium to 30-day VWAP and 42% to pre-speculation close on May 19, 2025.
Merger expected to close around year-end 2025, subject to Akero shareholder vote, antitrust clearance, and other conditions.
Termination fees: Akero pays $165M under certain circumstances; Novo Nordisk pays $185M reverse fee if antitrust conditions not met.
Board adopted forum selection bylaw amendment on October 8, 2025; transaction will supplement Novo Nordisk's GLP-1 metabolic portfolio.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Akero Therapeutics, Inc.: The Company amended its Bylaws to update the forum selection provision in Article VI, Section 8 (effective 2025-10-08).

Change: bylaw amendment
Effective: 2025-10-08

Exact text from the filing

On October 8, 2025, the Board approved and adopted an amendment (the “ Forum Selection Amendment ”) to the Company’s existing Bylaws that amends and replaces the existing Article VI, Section 8 forum selection provision. The Forum Selection Amendment is filed as Exhibit 3.1 hereto and incorporated by reference herein.

View on SEC.gov

244 governance changes filed in the last 30 days. Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-25-235919

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.